<unk>  is a monoclonal antibody developed by AbCellera and Eli Lilly as a treatment for COVID-19. Possible side effects include itching, rash, infusion-related reactions, nausea and vomiting.<unk>  works by binding to the spike protein of the virus that causes COVID-19, similar to other monoclonal antibodies that have been authorized for the treatment of high-risk people with mild to moderate COVID-19 and shown a benefit in reducing the risk of hospitalization or death.<unk>  is a neutralizing human immunoglobulin G1 (IgG1) monoclonal antibody, isolated from a patient who has recovered from the Coronavirus disease 2019 (COVID-19), directed against the spike (S) protein of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), that can potentially be used for immunization against COVID-19.<unk>  was granted an emergency use authorization (EUA) by the US Food and Drug Administration (FDA) in February 2022. The EUA for<unk>  is for the treatment of mild to moderate COVID-19 in people aged 12 years of age and older weighing at least with a positive COVID-19 test, and who are at high risk for progression to severe COVID-19, including hospitalization or death, and for whom alternative COVID-19 treatment options approved or authorized by the FDA are not accessible or clinically appropriate.<unk>  is not authorized for people who are hospitalized due to COVID-19 or require oxygen therapy due to COVID-19. Treatment with<unk>  has not been studied in people hospitalized due to COVID-19.
Bebtelovimab
Atoltivimab
Regdanvimab
Obiltoxaximab
Sotrovimab
Odesivimab
Nirsevimab
Maftivimab